Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 51, No 4 (2013)
Original paper
Submitted: 2014-02-05
Accepted: 2014-02-05
Published online: 2014-02-05
View PDF Download PDF file
Get Citation

Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma

Anna Glajcar, Karolina Kaczmarczyk, Joanna Szpor, Krzysztof Okon
DOI: 10.5603/FHC.2013.0044
·
Folia Histochem Cytobiol 2013;51(4):326-332.

open access

Vol 51, No 4 (2013)
ORIGINAL PAPERS
Submitted: 2014-02-05
Accepted: 2014-02-05
Published online: 2014-02-05

Abstract

Abstract: The current treatment of breast cancer, the most frequent malignancy found in females, requires the study of biomarkers. The standard set of these includes at least an estrogen receptor, a progesterone receptor and a HER2 receptor, although many other factors have been shown to contribute to the prognosis. Tissue microarrays have been introduced to decrease costs and workload of immunohistochemistry applied to large collections of samples. The aim of the study was to test the performance of this technology on three basic biomarkers of breast carcinoma in 106 cases of invasive breast carcinoma. Tissue microarrays composed of 3 cores sized 0.6 mm per case were constructed and stained by standard immunohistochemistry. The results were assessed on virtual slides created with an Aperio scanner. A sensitivity and specificity of 0.83 and 0.88 was obtained for the estrogen receptor, 0.76 and 0.88 for the progesterone receptor, 0.69 and 0.96 for HER2. In conclusion, TMA technology may give results comparable to the diagnosis based on whole sections, and the clinicopathologic correlations for the immunohistochemistry performed by both methods are fairy similar.

Abstract

Abstract: The current treatment of breast cancer, the most frequent malignancy found in females, requires the study of biomarkers. The standard set of these includes at least an estrogen receptor, a progesterone receptor and a HER2 receptor, although many other factors have been shown to contribute to the prognosis. Tissue microarrays have been introduced to decrease costs and workload of immunohistochemistry applied to large collections of samples. The aim of the study was to test the performance of this technology on three basic biomarkers of breast carcinoma in 106 cases of invasive breast carcinoma. Tissue microarrays composed of 3 cores sized 0.6 mm per case were constructed and stained by standard immunohistochemistry. The results were assessed on virtual slides created with an Aperio scanner. A sensitivity and specificity of 0.83 and 0.88 was obtained for the estrogen receptor, 0.76 and 0.88 for the progesterone receptor, 0.69 and 0.96 for HER2. In conclusion, TMA technology may give results comparable to the diagnosis based on whole sections, and the clinicopathologic correlations for the immunohistochemistry performed by both methods are fairy similar.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

breast cancer; tissue microarrays; prognostic factors; ER; PR; HER2

About this article
Title

Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 51, No 4 (2013)

Article type

Original paper

Pages

326-332

Published online

2014-02-05

Page views

1021

Article views/downloads

1709

DOI

10.5603/FHC.2013.0044

Bibliographic record

Folia Histochem Cytobiol 2013;51(4):326-332.

Keywords

breast cancer
tissue microarrays
prognostic factors
ER
PR
HER2

Authors

Anna Glajcar
Karolina Kaczmarczyk
Joanna Szpor
Krzysztof Okon

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl